Opto-Acoustic Imaging of Drug Discovery Biomarkers

Author(s): Bohumil Bednar, Vasilis Ntziachristos

Journal Name: Current Pharmaceutical Biotechnology

Volume 13 , Issue 11 , 2012

Become EABM
Become Reviewer


Optical imaging has seen significant developments over the past decade as an investigational tool for in-vivo visualization of cellular and sub-cellular events. With the recent addition of optoacoustic (photoacoustic) methods, in particular multi-spectral opto-acoustic tomography (MSOT), to the already rich armamentarium of photonic methods the capacity of optical molecular imaging across scales has widened significantly. MSOT brings unique features into optical imaging, namely high resolution optical imaging over several millimeters to centimeters of tissue depth and the ability to simultaneously resolve multiple tissue molecules and extrinsically administered optical or optoacoustic agents with physiological or molecular specificity. Here, we discuss the implications of utilizing MSOT in the context of drug discovery and review suitable optoacoustic agents against disease and drug efficacy biomarkers. The combination of existing knowledge on generating optical targeted contrast, with the high resolution deep tissue visualization offered by MSOT, allows for the development of next-generation biological optical imaging and corresponding drug discovery applications.

Keywords: Biomarkers, fluorochromes, imaging, optoacoustic, MSOT, optoacoustic (photoacoustic) methods, multi-spectral opto-acoustic tomography (MSOT), drug discovery, drug efficacy biomarkers, optical microscopy, Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Magnetic Resonance Imaging (MRI), Computed Tomography (CT)

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [2117 - 2127]
Pages: 11
DOI: 10.2174/138920112802502079
Price: $65

Article Metrics

PDF: 22